Literature DB >> 29046248

Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia.

Jung-Jr Ye1, Shian-Sen Shie2, Chun-Wen Cheng3, Jeng-How Yang4, Po-Yen Huang5, Ting-Shu Wu6, Ming-Hsun Lee7, Ching-Tai Huang8.   

Abstract

BACKGROUND: Vancomycin-resistant Enterococcus faecium (VRE-fm) bacteremia causes significant mortality in hospitalized patients. We sought to investigate clinical characteristics, treatment outcomes, and microbiological eradication associated with VRE-fm bacteremia.
METHODS: A retrospective cohort study was conducted and included 210 adult patients admitted between January 1, 2011 and December 31, 2015.
RESULTS: The mean Pitt bacteremia score was 4.7. ICU stay (48.6%) and mechanical ventilation (46.2%) were common. Diabetes mellitus was the most common concomitant disease (43.3%), followed by malignancies, including hematologic malignancies (14.3%) and solid cancers (28.1%). The 14-day and 28-day mortality rates were 37.1% and 50.5%, respectively. Linezolid or daptomycin treatment for at least 10 days and higher Pitt bacteremia scores were independently associated with 14-day and 28-day mortality. Longer treatment duration of linezolid or daptomycin predicted microbiological eradication independently. Daptomycin-treated patients tended to have higher 14-day and 28-day mortality, and lower microbial eradication rates (20.8% versus 8.7%; 40.6% versus 26.1%; 14.1% versus 26.1%; respectively) than linezolid-treated patients, and cumulative survival rates at 14 and 28 days tended to be lower in patients who received low-dose daptomycin (<10 mg/kg/day) than that in those who received linezolid and high-dose daptomycin (≥10 mg/kg/day); however, the differences were not statistically significant.
CONCLUSION: Higher disease severity and inappropriate treatment were associated with increased mortality and longer treatment duration of linezolid or daptomycin was associated with microbial eradication for the patient with VRE-fm bacteremia.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Bacteremia; Daptomycin; Enterococcus faecium; Linezolid; Vancomycin-resistant

Mesh:

Substances:

Year:  2017        PMID: 29046248     DOI: 10.1016/j.jmii.2017.08.025

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  8 in total

Review 1.  Sex differences in vancomycin-resistant enterococci bloodstream infections-a systematic review and meta-analysis.

Authors:  Carlos L Correa-Martínez; Franziska Schuler; Stefanie Kampmeier
Journal:  Biol Sex Differ       Date:  2021-05-17       Impact factor: 5.027

2.  Does Vancomycin Resistance Increase Mortality? Clinical Outcomes and Predictive Factors for Mortality in Patients with Enterococcus faecium Infections.

Authors:  Jatapat Hemapanpairoa; Dhitiwat Changpradub; Sudaluck Thunyaharn; Wichai Santimaleeworagun
Journal:  Antibiotics (Basel)       Date:  2021-01-22

3.  Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I).

Authors:  German A Contreras; Jose M Munita; Shelby Simar; Courtney Luterbach; An Q Dinh; Kirsten Rydell; Pranoti V Sahasrabhojane; Rafael Rios; Lorena Diaz; Katherine Reyes; Marcus Zervos; Helina M Misikir; Gabriela Sanchez-Petitto; Catherine Liu; Yohei Doi; Lilian M Abbo; Luis Shimose; Harald Seifert; Carlota Gudiol; Fernanda Barberis; Claudia Pedroza; Samuel L Aitken; Samuel A Shelburne; David van Duin; Truc T Tran; Blake M Hanson; Cesar A Arias
Journal:  Open Forum Infect Dis       Date:  2021-12-23       Impact factor: 4.423

4.  Antibiotic Stewardship Related to Delayed Diagnosis and Poor Prognosis of Critically Ill Patients with Vancomycin-Resistant Enterococcal Bacteremia: A Retrospective Cohort Study.

Authors:  Mu-Chun Yang; Yao-Kuang Wu; Chou-Chin Lan; Mei-Chen Yang; Sheg-Kang Chiu; Ming-Yieh Peng; Wen-Lin Su
Journal:  Infect Drug Resist       Date:  2022-03-01       Impact factor: 4.003

5.  Pharmacodynamics of Linezolid Plus Fosfomycin Against Vancomycin-Resistant Enterococcus faecium in a Hollow Fiber Infection Model.

Authors:  Shuaishuai Wang; Huiping Liu; Jun Mao; Yu Peng; Yisong Yan; Yaowen Li; Na Zhang; Lifang Jiang; Yanyan Liu; Jiabin Li; Xiaohui Huang
Journal:  Front Microbiol       Date:  2021-12-14       Impact factor: 5.640

6.  Understanding and Application of Daptomycin-Susceptible Dose-Dependent Category for Enterococcus: A Mixed-Methods Study.

Authors:  Jennifer L Adema; Laurel N Lake; Ryan W Stevens; Breann M Hogan; Audrey N Schuetz; Aaron J Tande; Kristin C Mara; Allison R Eberly; Christina G Rivera
Journal:  Open Forum Infect Dis       Date:  2022-01-10       Impact factor: 3.835

7.  Vancomycin-resistant enterococcal infection in a Thai university hospital: clinical characteristics, treatment outcomes, and synergistic effect.

Authors:  Jatapat Hemapanpairoa; Dhitiwat Changpradub; Sudaluck Thunyaharn; Wichai Santimaleeworagun
Journal:  Infect Drug Resist       Date:  2019-07-11       Impact factor: 4.003

8.  A silent outbreak of vancomycin-resistant Enterococcus faecium in a neonatal intensive care unit.

Authors:  Ronella Marom; Dror Mandel; Alon Haham; Irit Berger; Amit Ovental; Craig Raskind; Galia Grisaru-Soen; Amos Adler; Jonathan Lellouche; David Schwartz; Yehuda Carmeli; Vered Schechner
Journal:  Antimicrob Resist Infect Control       Date:  2020-06-16       Impact factor: 4.887

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.